Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Health Corp., a leading Canadian cannabis distributor. From July 2017 to February 2019, Mr. Scorsis served as the Chief Executive Officer and Director of Liberty Health Sciences. From January 2015 to April 2018, Mr. Scorsis has served as Chairman of the Board of Directors of SOL Global Investments Corp. (formerly known as Scythian Biosciences Corp.) Mr. Scorsis also currently serves as the Chairman of Entourage Health Corp. (since February 2019) and Chairman of AWAKN Life Sciences (since January 2017), both of which are publicly traded on the TSX Venture Exchange and NEO Exchange.
George Scorsis, newly appointed Chairman of the Shuttle Pharma Board of Directors, commented, 'I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.'
About Shuttle Pharmaceuticals
Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as the Company's other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle PharmaceuticalsChris Cooper Chief Executive Officer info@shuttlepharma.com
Investor ContactsLytham Partners, LLCshph@lythampartners.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Mizuho Reduces PT on PayPal Holdings, Inc. (PYPL)
With strong hedge fund interest and a low price-to-earnings ratio, PayPal Holdings, Inc. (NASDAQ:PYPL) secures a place on our list of the . Following the company's Q2 earnings release, Mizuho reduced its price target on PayPal Holdings, Inc. (NASDAQ:PYPL) from $87 to $84 on July 30, 2025. The analyst attributed the price revision to a slight dip in branded checkout growth and softer-than-expected transaction margin dollar guidance for the second half of 2025. Meanwhile, the company's core PayPal button business delivered strong performance when 'Buy Now Pay Later' and 'Pay with Venmo' segments are included. The latter segment is estimated to deliver 1.5 times the company-wide transaction margin. Furthermore, Barclays maintained its 'Buy' rating on PayPal Holdings, Inc. (NASDAQ:PYPL) on July 30 with a $90 target, and Needham maintained a 'Hold' rating the same day. Needham cited short-term e-commerce headwinds and modest EPS growth expectations. With its global technology platform, PayPal Holdings, Inc. (NASDAQ:PYPL) allows consumers to send, receive, and manage digital payments through multiple funding sources and channels. It is included in our list of the most undervalued value stocks to buy. While we acknowledge the potential of PYPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
an hour ago
- Yahoo
Apple Inc. (AAPL) Announces New Releases in Apple Arcade Segment
With a year-to-date decline in share price, along with strong hedge fund interest, Apple Inc. (NASDAQ:AAPL) secures a place on our list of the . brandon-romanchuk-NOFyRmSQfUQ-unsplash On August 12, 2025, Apple Inc. (NASDAQ:AAPL) announced new releases in its Apple Arcade segment, reinforcing its strategy to grow recurring revenue streams beyond hardware sales. As per the announcement, NFL Retro Bowl '26 will release on September 3, featuring a new Championship Leadership mode, which is synced with real NFL matchups. Also, Jeopardy! Daily and My Talking Tom Friends+ will be released on the same day. Featuring new characters and quests, Hello Kitty Island Adventure will launch its 'Wheatflour Wonderland' update later in the month. Looking ahead, Apple Inc. (NASDAQ:AAPL)'s long-term growth strategy is driven by its Apple Arcade's evolving catalog, offering over 200 ad-free games. Across its products like iPhone, iPad, Mac, and Apple TV, Apple Inc. (NASDAQ:AAPL) offers unlimited access to over 200 premium, ad-free games through its subscription-based gaming service, Apple Arcade. It is included in our list of the Best Rebound Stocks To Buy. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best AI Stocks to Buy Under $3 and Bill Ackman Stock Portfolio: Top 10 Stock Picks. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here's the forecast for the Tesla share price
The Tesla (NASDAQ:TSLA) share price is very volatile for a mega-cap stock. The company has long excited investors with its futuristic ambitions, from fully autonomous vehicles to humanoid robots, and even operations on Mars. However, analysts are increasingly cautious about the valuation despite the bold promises. The price target The average 12-month price target from 37 Wall Street analysts is currently $307.23. That's compared to a share price of $335.58 as I write. Forecasts vary widely, with a high of $500 and a low of just $19. The consensus suggests that the stock's overvalued however, it's around fair value if we exclude GLJ Research's incredibly bearish take. But Tesla's valuation metrics should make investors think twice. Its forward price-to-earnings (P/E) ratio's an insane 198.87 times. That's more than 1,000% higher than the consumer discretionary sector median. Other indicators — including enterprise value-to-EBIT, price-to-sales, and price-to-cash flow — are also clearly elevated. Optimism baked in Much of the optimism baked into the share price concerns Tesla's ambitions beyond electric vehicles (EVs). As we know, CEO Elon Musk has repeatedly suggested that Robotaxis and the humanoid robot Optimus could transform the company's future and justify a far higher valuation. However, timelines for both are relatively vague. And there have been a few disappointments of late. The full rollout of Robotaxis has faced several delays, and full regulatory approval for autonomous vehicles remains a significant hurdle. Optimus, meanwhile, still appears far from commercialisation. Even if these technologies prove viable, questions remain over consumer adoption, pricing power, and competitive threats from other automakers and tech firms. In the case of robotaxis, infrastructure, insurance frameworks, and city-level policy are all really important, but none of these are within Tesla's direct control. As for Optimus, while the demo videos have drawn headlines, the path from prototype to scalable, revenue-generating product is uncertain. Investors may be underestimating how long it could take before either platform contributes materially to Tesla's earnings. The bottom line Investors have been here before. Some argue that the firm has a track record of delivering against the odds, particularly in scaling its EV operations. Yet recent numbers suggest growth may be slowing. What's more, the consensus forecasts show earnings per share (EPS) falling 30% in 2025. While there will likely be a rebound in later years, this is a considerable drop. Analysts anticipate EPS growth of 82% by 2028, though such long-range estimates are inherently uncertain. There's also not many analysts forecasting through to 2028. This puts investors in a challenging position. While the long-term vision's exciting, today's share price is heavily reliant on future breakthroughs rather than current performance. For those who believe in Tesla's ability to disrupt multiple industries, the current price might still make sense. However, I believe it's still a rather speculative investment. And that's simply because those valuation figures are incredibly hard to justify. As much as I like the brand, I don't think investors should consider the stock right now. The post Here's the forecast for the Tesla share price appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended Tesla. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
